Abstract
Objective: Irbesartan is an antihypertensive with limited bioavailability. The objective of the study was to develop controlled release matrix tablets of irbisartan drug.
 Methods: Tablets were prepared by wet granulation process. Result: In vitro drug release study revealed that HPMC causes initial burst release of drug hence combining HPMC sustained the action for 8 h (95.92±0.57% release). Fitting the in vitro drug release data to Korsmeyer equation indicated that diffusion along with erosion could be the mechanism for drug release. Compared to conventional tablets, the release of model drug from these HPMC matrix tablets was prolonged, leading to achieve an effective therapy with a low dosage of the drug, to reduce the frequency of medication. The pharmacological and clinical properties of irbesartan, a noncompetitive angiotensin II receptor type 1 antagonist, successfully used for more than a decade in the treatment of essential hypertension.
 Results: Compatibility Studies In order to investigate the possible interactions between irbesartan and distinct polymers and/or diluents, FT-IR and DSC studies were carried out. FT-IR results proved that the drug was found to be compatible with excipients as wave numbers are almost similar for pure drug and also drug excipients mixture. In picture 1 and 2. DSC studies indicate that chosen excipients for the formulation were found to be compatible with the active ingredient as the melting endothermic peaks are in the range of 250-320 °C which is same as the melting point of irbisartan.
 Conclusion: Irbesartan exerts its antihypertensive effect through an inhibitory effect on the pressure response to angiotensin II. Irbesartan 150–300 mg once daily confers a lasting effect over 24 h, and its antihypertensive efficacy is further enhanced by the coadministration of hydrochlorothiazide.
Highlights
Hydrogel the most promising alternative drug delivery systems for improving the bioavailability and therapeutic availability of the drugs
The swelling rate and erosion of HPMC-based matrix tablet in aqueous media are very crucial in terms of achieving the desired release profiles and are affected by parameters such as the physicochemical properties of the polymer and the drug, processing conditions, the testing medium used and the formulation composition
DSC studies indicate that chosen excipients for the formulation were found to be compatible with the active ingredient as the melting endothermic peaks are in the range of 250-320 °C which is same as the melting point of irbisartan
Summary
Hydrogel the most promising alternative drug delivery systems for improving the bioavailability and therapeutic availability of the drugs. High patient compliance and flexibility in designing dosage forms attracted the oral drug delivery systems to be the most convenient mode of drug administration when compared to other dosage forms. Hydrophilic matrix tablets are among the most popular delivery systems for oral controlled release dosage forms. These hydrophilic matrices are widely accepted because of their biopharmaceutical and pharmacokinetics advantages over conventional dosage forms. This is largely because they offer exact modulation of drug release as a result of hydration of the constituent polymer(s), flexibility to obtain desired drug release profiles, cost-effectiveness, patient compliance, providing a constant, prolonged, and uniform therapeutic effect and broad Food and Drug Administration (FDA) acceptability. The swelling rate and erosion of HPMC-based matrix tablet in aqueous media are very crucial in terms of achieving the desired release profiles and are affected by parameters such as the physicochemical properties of the polymer and the drug, processing conditions, the testing medium used and the formulation composition
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
